Heal - development and implementation of a provider prescribed, behavioral digital therapeutic designed to support, educate, screen and remotely monitor patients with chronic pain - 2MORROW, INC
Ended Project Grant Awarded Last action
- Award ID
- R44AT011593
- Recipient
-
2Morrow Inc. UEI ZS1JSAKF9FK7
- Awarding agency
-
National Center for Complementary and Integrative Health
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,618,132
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Funding
-
- $3,366,146.00 Federal
- $251,986.00 Non-federal
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- Place of performance
- Kirkland, WA 98034, USA
Award details come from USAspending.gov.
Description
- Abstract
- 2MORROW, INC. Was established in 2011 to develop mobile technology for increasing access to evidence-based healthcare. 2MORROW's programs use acceptance and commitment therapy (act), a behavioral approach that helps guide users through unhelpful thoughts, feelings and urges. Using act, we have created and marketed highly successful self-management programs for multiple disorders including chronic pain. Proposed product: we have learned from our chronic pain self-management program that act reduces anxiety disorders and depression which typically accompany chronic pain and provides the patient with coping strategies for managing their CP. These CP-associated problems challenge primary care providers (PCPS) who do not have the capacity to manage the mental health and behavioral components of chronic pain. To address these challenges, we will develop a new product, 2MRX- CP, a prescription digital therapeutic (PDT), that will combine our established act protocols for CP management with screening tools for SUD, anxiety, and depression. IT will also include: 1) behavioral science content; and 2) remote patient monitoring (RPM) that evaluates CP patient outcome metrics and sends them to a provider dashboard to inform PCPS. We are seeking a fast-track sbir application as 2MORROW has already established itself in the digital health realm and will use their existing platforms to inform our 2MRX-CP product development. Our 4 phase I specific aims are: 1) conduct a quantitative evaluation of the existing 2MORROW chronic pain self-management digital health program to address dissemination and implementation variables of appropriateness, acceptability, and feasibility; 2) conduct a qualitative study of PCP core teams to: a) determine best fit PCP clinic types for 2MRX-CP for the phase II clinical study & our marketing strategy; and B) initiate development of the provider dashboard; 3) to initiate development of our new prescription-based digital program, 2MRX-CP, by reviewing data collected in aims I-1 and 2, then developing a paper protocol of program core elements; and 4) 2MORROW will contract consultants to complete an audit of our current quality management processes and procedures to inform the formalized phase II QMS implementation. Our 4 phase II specific aims are: 1) conceptually design and build 2MRX-CP by incorporating the outcomes from phase I to create final content, screening tools, algorithms, and user experiences in an FDA compliant QMS IOS and android mobile application; 2) conduct a clinical trial of 20 providers and 100 patients, as determined by our power analysis, that will focus on impact of APP use on change in primary patient reported outcomes and to describe patient reported implementation outcomes: 1) patient outcomes on pain interference, function, depression, and anxiety, and 2) implementation outcomes on acceptability, appropriateness, feasibility, fidelity, costs, and sustainability of use by patients; and 4) conduct likert-based on-line surveys of PCP use of the provider dashboard each month for 6 MOS of the SA II-2 clinical study followed by tracking PCP post-study PDT use and by PCP interviews.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $498,970 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,181,602 | $0 | |
| Amendment | $1,181,602 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $251,986 | $0 | |
| Original award | $251,986 | $251,986 |
Show all 13
Quick answers
Who received award R44AT011593?
R44AT011593 was awarded to 2Morrow Inc. by National Center for Complementary and Integrative Health (National Institutes of Health) on May 1, 2021.
How much is award R44AT011593 worth?
$3,618,132 has been obligated on R44AT011593: $3,366,146 in federal funding and $251,986 in non-federal funding.
Which agency awarded R44AT011593?
National Center for Complementary and Integrative Health (National Institutes of Health) awarded R44AT011593, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award